B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery ( P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence ( P < 0.001 and P = 0.005) and cancer-specific death ( P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, overexpression of B7H3 is associated with disease spread, including increased extracapsular extension and seminal vesicle invasion, as well as worse outcomes, including higher risk of metastatic recurrence or subsequent development of CRPC88.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citation
Cited by
Items 201–300 of 420
High B7‐H3 expression is linked to increased risk of prostate cancer progression
Bonk, S., Tasdelen, P., Kluth, M., Hube‐Magg, C., Makrypidi‐Fraune, G., Möller, K., Höflmayer, D., Rico, S. D., Büscheck, F., Minner, S. J. P., et al. (2020) · Pathology International · doi:10.1111/pin.12999 · Cited by 27
Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer
Li, Z., Wang, J., Chen, G., Shan, Z., Wang, T., Shen, Y., Chen, J., Yan, Z., Peng, L., Mao, F.-Y., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108753 · Cited by 27
Kachroo, N., & Gnanapragasam, V. J. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1351-7 · Cited by 26
Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection
Hofmeyer, K. A., Scandiuzzi, L., Ghosh, K., Pirofski, L., & Zang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200701 · Cited by 26
Self-citationPizon, M., Schott, D. S., Pachmann, U. A., & Pachmann, K. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4551 · Cited by 26
B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients
Liu, W., Shibata, K., Koya, Y., Kajiyama, H., Senga, T., Yamashita, M., & Kikkawa, F. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.225 · Cited by 25
Vaishnav, J., Khan, F., Yadav, M., PARMAR, N. R., Buch, H., Jadeja, S. D., Dwivedi, M., & Begum, R. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152274 · Cited by 25
Alternative Checkpoints as Targets for Immunotherapy
Pant, A., Medikonda, R. T., & Lim, M. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00983-y · Cited by 25
Yoon, B. R., Chung, Y., Yoo, S.-J., Kawara, K., Kim, J., Yoo, I. S., Park, C., Kang, S. W., & Lee, W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.680298 · Cited by 25
Diagnosis value of serum soluble B7‐H4 expression in non‐small cell lung cancer
Xu, C., Wang, W., Wang, Y. C., Lin, Y., & Zhang, X. W. (2016) · The Clinical Respiratory Journal · doi:10.1111/crj.12499 · Cited by 24
Yang, J. H., Kim, H., Roh, S. Y., Lee, M. A., Park, J. M., Lee, H. H., Park, C. H., Lee, H. H., Jung, E. S., Lee, S. H., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0842-x · Cited by 25
B7-H3 and its role in bone cancers
He, L., & Li, Z. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.012 · Cited by 24
Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3
Oroujeni, M., Bezverkhniaia, E., Xu, T., Liu, Y., Plotnikov, E. V., Karlberg, I., Ryer, E., Orlova, A., Максимилианович, Т. В., & Frejd, F. Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091780 · Cited by 24
“variety of cancers, such as prostate [8,9], renal cell carcinoma [10], urothelial cell carcinoma [11], ovarian cancer [12], glioblastoma [13], osteosarcoma [14], pancreatic cancer [15], neuroblastoma [16], diffuse intrinsic pontine glioma [17] and mesothelioma [18].”
BackgroundCould B7-H4 serve as a target to activate anti-cancer immunity?
Wang, L., Heng, X., Lu, Y., Cai, Z., Yi, Q., & Che, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.020 · Cited by 23
IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
Lutz, M. S., Zekri, L., Wessling, L., Berchtold, S., Heitmann, J. S., Lauer, U. M., Jung, G., & Salih, H. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1163136 · Cited by 22
“High expression of B7-H3 on tumor tissue is associated with poor clinical outcome and lymph node metastasis (43), and several studies report first evidence that B7-H3 positive tumor cell fractions may be enriched for cancer stem cells (44–46).”
BackgroundWang, F., Daylan, A. E. C., Deng, L., Yang, J., Sharma, J. N., Su, C. T., Li, S., Zang, X., Halmos, B., Borczuk, A., et al. (2023) · Cancers · doi:10.3390/cancers15133372 · Cited by 22
“1 [15,32] N/A 1:500, incubate overnight at 4 ◦C B7-H3 Polyclonal N/A R&D sciences [33] BAF1027 5 μg/mL, incubate overnight at 4 ◦C”
Self-citationWhitmore, T. E., Peterson, A. C., Holzman, T., Eastham, A., Amon, L. M., McIntosh, M. W., Ozinsky, A., Nelson, P. S., & Martin, D. B. (2012) · Journal of Proteome Research · doi:10.1021/pr201200n · Cited by 22
B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms
LIU, W.-H., CHEN, Y.-Y., ZHU, S.-X., Li, Y., Xu, Y., WU, X.-J., GUO, Y.-H., & Wang, J. C. (2014) · Oncology Letters · doi:10.3892/ol.2014.2522 · Cited by 22
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3
Li, N., Spetz, M. R., Li, D., & Ho, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107892 · Cited by 22
Stefanczyk, S. A., Hagelstein, I., Lutz, M. S., Müller, S., Holzmayer, S. J., Jarjour, G., Zekri, L., Heitmann, J. S., Salih, H. R., & Märklin, M. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01050-6 · Cited by 21
Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis
Song, X., Shao, Y., Gu, W., Xu, C., Mao, H., Pei, H., & Jiang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8598 · Cited by 21
Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?
Lin, D., Wang, X., Choi, S. Y. C., Ci, X., Dong, X., & Wang, Y. Z. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.002 · Cited by 21
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors
Yuan, Z., Gardiner, J. C., Maggi, E. C., Huang, S., Adem, A., Bagdasarov, S., Li, G., Lee, S. Y., Slegowski, D., Exarchakis, A., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0337 · Cited by 21
Self-citationA Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
Feng, Y., Xie, K., Yin, Y., Li, B., Pi, C., Xu, X., Huang, T., Zhang, J., Wang, B., Gu, H., et al. (2022) · Life · doi:10.3390/life12020157 · Cited by 21
B7-H4 Expression in Normal and Diseased Human Islet β Cells
Cheung, S. S. C., Ou, D., Metzger, D. L., Meloche, M. R., Ao, Z., Ng, S. S. W., Owen, D., & Warnock, G. L. (2013) · Pancreas · doi:10.1097/mpa.0b013e31829695d2 · Cited by 21
Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice
Yin, S. J., Wang, W., & Zhang, J. Y. (2015) · Genetics and Molecular Research · doi:10.4238/2015.november.13.9 · Cited by 21
Calabrò, L., Sigalotti, L., Fonsatti, E., Bertocci, E., Giacomo, A. M. D., Danielli, R., Cutaia, O., Colizzi, F., Covre, A., Mutti, L., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22600 · Cited by 21
“…tumor histotypes have also been showed to express B7-H3 (Castriconi et al., 2004; Sun et al., 2006, 2010; Wu et al., 2006; Roth et al., 2007; Zang et al., 2007, 2010; Chen et al., 2008; Crispen et al., 2008; Gregorio et al., 2008; Loos et al., 2009) suggesting for a potential dual role of…”
BackgroundThe evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
Hagelstein, I., Engel, M., Hinterleitner, C., Manz, T., Märklin, M., Jung, G., Salih, H. R., & Zekri, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1002898 · Cited by 20
“Overexpression of B7-H3 is linked to unfavorable disease course and poor prognosis for patients (25, 31, 32) and has been suggested to”
BackgroundZhou, L., Wu, J., Ruan, M., Xiao, Y., Lan, H., Wu, Q., Yu, D. C. W., & Zhang, Q. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01721-5 · Cited by 20
“B7-H4 was found to be constitutively expressed in several cancer cells including ovarian cancer [12], prostate cancer [13], melanoma [14] and invasive ductal and lobular breast cancers [15–17].”
BackgroundA promising target for breast cancer: B7-H3
Jiang, Y., Liu, J., Chen, L., Qian, Z., & Zhang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-11933-3 · Cited by 20
“The expression of B7-H3 on the surfaces of tumor cells stimulates the growth of tumors by allowing these cells to evade immunosurveillance [23]; Compared to normal tissues, tumor tissues have an excessive expression of B7-H3 [24, 25].”
BackgroundZhang, L., Jin, Y., Xia, P., Lin, J., Ma, J., Li, T., Liu, Z., Xiang, H., Chen, C., Xu, Z., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4284 · Cited by 20
Xiao, Z., Jin-yin, L., Yu, Q., Zhou, T., Duan, J., Yang, Z., Liu, C., & Xu, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778294 · Cited by 20
“CD276 has been reported to promote tumor progression by inhibiting the functions of NK and CD8 T cells, and its expression levels were associated with poor prognosis in multiple cancers (Zang et al., 2007; Crispen et al., 2008; Zhang et al., 2009; Lee et al., 2017; Inamura et al., 2018).”
BackgroundThe characteristic expression of B7-associated proteins in Langerhans cell sarcoma
Li, H., Wang, C., Guo, G., Gao, C., Wu, Y., & Chen, Y. (2012) · Acta Histochemica · doi:10.1016/j.acthis.2011.12.010 · Cited by 20
B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
Jansen, L., Wienke, J., Molkenbur, R., Rössig, C., & Meissner, R. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10294-y · Cited by 19
“Various studies found expression of B7-H3 in tumors to be associated with poor prognosis [17, 19, 53–55].”
Johnson, M. L., Patel, M. R., Falchook, G. S., Koyama, T., Gutierrez, M., Awad, M. M., Piha-Paul, S. A., Friedman, C. F., Satoh, T., Okamoto, N., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00733-8 · Cited by 19
B7-H4 induces epithelial–mesenchymal transition and promotes colorectal cancer stemness
Feng, Y., Yang, Z., Zhang, C., Che, N., Liu, X., & Xuan, Y. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153323 · Cited by 19
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma
Mao, Y., Ding, W., Fu, F., Wang, H., Sun, Z., Huang, Z., Wang, Y., Zhang, G., Zhang, X., Jiang, B., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115489 · Cited by 19
Radichev, I., Maneva-Radicheva, L., Amatya, C., Salehi, M., Parker, C., Ellefson, J., Burn, P., & Savinov, A. Y. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1403251 · Cited by 19
Development of Novel Immune Interventions for Prostate Cancer
Agarwal, N., Padmanabh, S., & Vogelzang, N. J. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.01.012 · Cited by 19
“Overexpression of B7x and related coinhibitory ligand B7-H3 also is associated with a higher risk of invasive disease, metastases, and recurrence in prostate cancer.(16,17)”
BackgroundFan, T. (2026) · American Journal of Translational Research · doi:10.62347/lasv4520 · Cited by 19
Kaur, G., & Janakiram, M. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000554 · Cited by 19
“B7-H3 and B7x are highly expressed in human prostate cancer and was associated with disease spread and poor outcomes.(12) B7x expression was evaluated in 259 renal cell carcinoma (RCC) cases and the protein was present in 59.”
BackgroundMolecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues
Sequeiros, T., García, M., Montes, M., Oliván, M., Rigau, M., Colás, E., de Torres, I. M., Moróte, J., Reventós, J., & Doll, A. (2013) · BioMed Research International · doi:10.1155/2013/283635 · Cited by 19
Chen, L., Xie, Q., Wang, Z., Shi, L., Wu, C., & Jiang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12628 · Cited by 19
DeSantes, K. B., McDowell, K. A., Sondel, P. M., Hutson, P. R., Kaplan, R. N., Park, J. R., Hegde, M. G., Mackall, C. L., & Maris, J. M. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0293 · Cited by 18
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer
Zhang, Q., Zong, L., Zhang, H., Xie, W., Yang, F., Sun, W., Cui, B., & Zhang, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s318082 · Cited by 18
B7x in cancer immunity and immunotherapy
Mortezaee, K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110133 · Cited by 18
Interaction of Immune and Cancer Cells
Klink, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4 · Cited by 18
In Vivo Function of Immune Inhibitory Molecule B7-H4 in Alloimmune Responses
Yamaura, K., Watanabe, T., Boenisch, O., Yeung, M. Y., Yang, S., Magee, C. N., Padera, R. F., Datta, S., Schatton, T., Kamimura, Y., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03250.x · Cited by 18
Strömvall, K., Thysell, E., Bergström, S. H., & Bergh, A. R. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176679 · Cited by 18
B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment
Ott, J. M., Gassenmaier, V., Bitzer, M., Schürch, C. M., Heitmann, J. S., & Hagelstein, I. (2025) · Pathology & Oncology Research · doi:10.3389/pore.2025.1612186 · Cited by 17
Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer
Kang, N., Xue, H., Lin, Y., Dong, X., Classen, A., Wu, R., Jin, Y., Lin, D., Volik, S. V., Ong, C. J., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00644-9 · Cited by 17
B7-H3 suppresses CD8+ T cell immunologic function through reprogramming glycolytic metabolism
Wu, Y., Han, W., Tang, X., Liu, J., Guo, Z., Li, Z., Cai, C., & Que, L. (2024) · Journal of Cancer · doi:10.7150/jca.90819 · Cited by 17
Wei, X., Zhang, G., Yuan, H., Ding, X., Li, S., Zhang, X., & Hou, J. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.09.104 · Cited by 17
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies
Babič, D., Jovčevska, I., & Zottel, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495283 · Cited by 16
Prognostic Role of B7-H3 (CD276) Expression in Initial Biopsies of Metastatic Prostate Cancer
Yusuf, A., & Pramanik, P. (2025) · Onco · doi:10.3390/onco5030038 · Cited by 16
Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer
Azuma, T., Sato, Y., Ohno, T., Azuma, M., & Kume, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243379 · Cited by 16
Ahangar, N. K., Hemmat, N., Khalaj‐Kondori, M., Shadbad, M. A., Sabaie, H., Mokhtarzadeh, A., Alizadeh, N., Derakhshani, A., Baghbanzadeh, A., Dolatkhah, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052652 · Cited by 16
Development of a novel monoclonal antibody to B7-H4: characterization and biological activity
Qian, Y., Shen, L., Xu, C., Wu, Z., Brockmeyer, N. H., Altmeyer, P. J., Wu, N., & Yao, H. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-7-295 · Cited by 16
“In contrast, an increasing number of studies using human tumor samples have revealed that b7-H4 is overexpressed in various tumors, including breast [5-6], ovarian [5, 7], renal [8], prostate [9], and non-small cell lung cancers [10], and that b7-H4 expression, as assessed using Rt-PcR and IHc, is associated with dise…”
BackgroundPrognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis
Tan, Z., & Shen, W. (2017) · Oncotarget · doi:10.18632/oncotarget.15648 · Cited by 15
Inhibitors of B7–CD28 Costimulation in Urologic Malignancies
Thompson, R. H., Kwon, E. D., & Allison, J. P. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.129 · Cited by 15
Self-citationAdvances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
Chen, S., Zhan, S., Ding, S., Zhang, Q., Xuan, H., Zhang, X., & Cao, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05408-4 · Cited by 14
“However, B7-H3 is significantly overexpressed in various tumor tissues, including prostate, ovarian, colorectal, pancreatic, and gastric cancers (Zang et al. 2007, 2010; Ingebrigtsen et al. 2012; Zhan et al. 2020; Shao et al. 2022).”
BackgroundPrognostic Significance of B7H3 Expression in Solid Tumors: A Systematic Review and Meta-Analysis
Mielcarska, S., Kula, A., Dawidowicz, M., Waniczek, D., & Świętochowska, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073044 · Cited by 14
“( study on B ) One-leave meta-analysis for assessing the influence of excluding a particular study on pooled HR for DSS in solid tumors [17,20,27,28,30,32,34–37, 42, 44– 46,54”
Yang, M. S., Tian, S., Lin, Z., Fu, Z., & Li, C. (2022) · Medicine · doi:10.1097/md.0000000000031667 · Cited by 14
Scutti, J. B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4283 · Cited by 14
Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
Hu, J., Jiang, C., Zheng, M., Guo, Y.-X., Tang, X., Ren, J. L., Lu, D., Yu, L., Gan, W., Liu, S., et al. (2019) · Europe PMC (PubMed Central) · Cited by 14
Mach, P., Gellhaus, A., Wicherek, Ł., Schmidt, B., Kimmig, R., Kasimir‐Bauer, S., & Köninger, A. (2015) · American Journal of Reproductive Immunology · doi:10.1111/aji.12392 · Cited by 14
Jiang, Y., Cai, G., Lin, J., Zhang, J., Bo, Z., Li, Y., Wang, C., & Tong, Y. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0234-9 · Cited by 14
Yusuf, A., & Pramanik, P. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2508.09373 · Cited by 14
Palmitic acid-triggered B7H3 palmitoylation promotes immune escape
Rao, Z., Huang, C., Wu, Q., Li, M., Liu, A., Zhu, T., Yang, W., Yin, L., Zhu, S., She, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68525-x · Cited by 13
Chand, D., Dhawan, D., Sankin, A. I., Ren, X., Lin, J., Schoenberg, M., Knapp, D. W., & Zang, X. (2019) · Bladder Cancer · doi:10.3233/blc-180204 · Cited by 13
“Its expression in normal tissues is limited, however it is detected in a myriad of cancers including human bladder cancer [7, 8].”
BackgroundSelf-citationChapoval, A. I., Chapoval, S. P., Shcherbakova, N. S., & Щербаков, Д. Н. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019050091 · Cited by 13
Expression of Costimulatory Molecule B7-H4 in Human Malignant Tumors
Zheng, X. W., Li, X., Wu, C., Lu, B., & Jiang, J. (2012) · Onkologie · doi:10.1159/000343638 · Cited by 13
B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis
Meng, Z., Wang, F., Zhang, Y., Li, S., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18566 · Cited by 13
Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3
Oroujeni, M., Bezverkhniaia, E., Xu, T., Liu, Y., Plotnikov, E. V., Klint, S., Ryer, E., Karlberg, I., Orlova, A., Frejd, F. Y., et al. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108384 · Cited by 12
“…is overexpressed with high frequency in many different cancer types e.g. neuroblastoma [2], melanoma [3], glioblastoma [4], non-small cell lung cancer [5], pancreatic [6,7], breast [8], prostate [9,10] and ovarian cancers [11], whereas its expression in most normal organs and tissues is low [12].”
Taghavi, B. A., Alizadeh, N., Saeedi, H., Ahangar, N. K., Derakhshani, A., Hajiasgharzadeh, K., Silvestris, N., Baradaran, B., & Brunetti, O. (2022) · Molecules · doi:10.3390/molecules27113545 · Cited by 12
Zhang, Q., Tang, Y., Hu, G., Yuan, Z., Zhang, S., Sun, Y., Yin, D., Dong, C., Zhao, J., Wu, G., et al. (2022) · PubMed Central · Cited by 12
Najjary, S., de Koning, W., Kros, J. M., & Mustafa, D. A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305644 · Cited by 12
Cifrić, S., Turi, M., Folino, P., Clericuzio, C., Barello, F., Maciel, T., Anderson, K. C., & Gullà, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0558 · Cited by 12
“…associated with poor immune infiltration and prognosis in patients with triple-negative breast cancer (TNBC) (Song et al., 2020), ovarian tumors (Kryczek et al., 2007), melanoma (Quandt et al., 2011), lung cancer (Sun et al., 2006), and prostate cancer (Podojil and Miller, 2017; Zang et al., 2007).”
Wang, S., & Jia, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_1 · Cited by 12
Feng, D., Wang, J., Shi, X., Li, D., Wei, W., & Han, P. (2023) · European journal of medical research · doi:10.1186/s40001-023-01132-4 · Cited by 12
Treatment of men with rising prostate-specific antigen levels following radical prostatectomy
Tzou, K. S., Tan, W. W., & Buskirk, S. J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.210 · Cited by 12
Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma
Hong, B., Qian, Y., Zhang, H., Sang, Y.-W., Cheng, L.-F., Wang, Q., Gao, S., Zheng, M., & Yao, H.-P. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i18.4538 · Cited by 12
B7-H3 protein expression in a murine model of osteosarcoma
ZHAO, J.-L., Chen, F., Zhou, Q., Pan, W., WANG, X.-H., Xu, J. Y., ZHANG, S.-X., Li, N., & Yang, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4675 · Cited by 12
Immune-Based Therapies for Metastatic Prostate Cancer: An Update
Hossain, M. K., Nahar, K., Donkor, O. N., & Apostolopoulos, V. (2018) · Immunotherapy · doi:10.2217/imt-2017-0123 · Cited by 12
Potential role of soluble B7‐H3 in liver immunopathogenesis during chronic HBV infection
Luan, Y., Ju, J., Luo, L., Zhang, Z., Wang, J., Zhu, D., Cheng, L., Zhang, S. ‐., Chen, L., Wang, F., et al. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01421.x · Cited by 12
Hashiguchi, M., Inamochi, Y., Nagai, S., Otsuki, N., Piao, J., Kobori, H., Kanno, Y., Kojima, H., Kobata, T., & Azuma, M. (2012) · Open Journal of Immunology · doi:10.4236/oji.2012.21002 · Cited by 12
“carcinomas of the prostate [14,20], kidney [21], lung [13],”
BackgroundGalustian, C., Vyakarnam, A., Elhage, O., Hickman, O. J., Dasgupta, P., & Smith, R. A. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391433 · Cited by 12
Zhou, Y., Zhang, G., Zhang, W., Wei, X., Hou, J., & Huang, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820971649 · Cited by 11
“Zang et al.11 also found that higher B7-H3 expression levels in prostate cancer tissues were associated with higher tumor metastasis, postoperative recurrence and mortality rates; however, the role of B7-H3 in tumor progression remains unclear.”
BackgroundAn Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
Lutz, M. S., Wang, K., Jung, G., Salih, H. R., & Hagelstein, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343929 · Cited by 11
Park, R., Yu, J., Shahzad, M., Lee, S., & Ji, J. D. (2024) · Immunologic Research · doi:10.1007/s12026-024-09458-9 · Cited by 11
Upregulation of the B7/CD28 family member B7-H3 in bladder cancer
Wu, D., Zhang, Z., PAN, H., FAN, Y., Qü, P., & Zhou, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2828 · Cited by 11
Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy
Hińcza, K., Kowalik, A., Walczyk, A., Pałyga, I., Gąsior‐Perczak, D., Płusa, A., Kopczyński, J., Chrapek, M., Góźdź, S. S., & Kowalska, A. (2021) · Genes · doi:10.3390/genes12101534 · Cited by 11
Xu, C., Qian, L.-H., Yu, L., Zhang, X., & Wang, Q. (2015) · Biomarkers · doi:10.3109/1354750x.2015.1068858 · Cited by 11
Guo, G., Cao, D., Xu, H., Ruan, Z., Fei, L., Xie, Z., Wu, Y., & Chen, Y. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02856.x · Cited by 11
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC
Wu, H., Liu, C., Yuan, Q., Qiao, Y., Ding, Y., Duan, L., Li, W., Zhang, M., Zhang, X., Jiang, Y., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2282250 · Cited by 10
Saeed, M. A., Peng, B., Kim, K., Rawat, K., Kuehm, L. M., Siegel, Z. R., Borkowski, A., Habib, N., Tine, B. A. V., Sheikh, N. A., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0652 · Cited by 11
Sankin, A. I., Narasimhulu, D. M., John, P., Gartrell, B. A., Schoenberg, M., & Zang, X. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.04.007 · Cited by 10
“Despite its restricted expression on healthy somatic tissues, B7x is frequently expressed in many cancer types including those of the breast, lung [52], colon [69], ovary [70], endometrium [71], kidney [72], pancreas [73], prostate [40], and bladder.”
InfluentialSelf-citationDeveloping Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer
Small, E. J., & Fong, L. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3483 · Cited by 10
Metadata
- Authors
- Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Chicago Medical Center (US)
- Pathology, and
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Allison, James P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-12-04
- Volume
- 104
- Issue
- 49
- Pages
- 19458-19463
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2148311
- OpenAlex
- W2164079212
- Cited by
- 401
- References
- 42
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 20 · 2023: 23 · 2022: 27 · 2021: 28 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 26 · 2016: 31 · 2015: 15 · 2014: 22 · 2013: 25 · 2012: 27
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- National Cancer Institute (T32CA082088)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- B7-H3, prostate cancer, B7/CD28 family, tumor immune evasion, tumor recurrence, cancer-specific mortality, lymph node metastasis, prognostic factors, immunotherapy targets, radical prostatectomy
- MeSH terms
- Humans, Immunohistochemistry, Male, Prognosis, Prostatic Neoplasms, Receptors, Immunologic, Antigens, CD, Survival Analysis, B7-1 Antigen, Disease Progression, B7 Antigens, V-Set Domain-Containing T-Cell Activation Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.